Editorial:
Aggressive Medicine Promotional Activity of Pharmaceutical Industry All Over the Globe: Who Will Do the Highly Risky Job to Defy the Monstrous Financial Tyrant?
Mainul Haque

Keywords: Pharmaceutical, Manufacturing, Belligerent, Drug, Advertising, Commotion, Dangerous, Work, Challenge, Atrocious, Monetarist, Autocrat.

“The proliferation of medical advertising is a symptom of the nation’s all-against-all vision of medicine as just another commodity.”

The pharmaceutical industries (PI) around the globe are belligerently intricate with medicine promotional, with a definite intention to transform the prescribing habits of medical doctors in favor of their marketed product to maximize the profit but not promote the healthcare system either locally or internationally. The current medicine promotional activities, especially in the Low- and Middle-Income Countries (LMICs), are at an extreme perturbing stage as very often LMICs regulatory agencies not much strong to control these urgent issues. Additionally, promotional activities frequently inspire self-purchasing medicine even those are prescription-only drugs. Antimicrobials are regularly available over the counter in many LMICs because of poor regulatory. Thereafter, both the PI and pharmacy/medicine shop took the opportunity to maximize the profit. 12-15

“The pharmaceutical industry spends roughly 15 billion dollars annually on detailing – providing gifts, information, samples, trips, honoraria, and other inducements – to physicians in order to encourage them to prescribe their drugs.”

It has been created a lot of discussion regarding the physician-pharma industry underhand relation for multiple decades. Acceptance of gift worth of millions of local or international currency from pharma rep has usual practice, and many occasions, physicians have a much positive attitude towards acceptance. Physicians around the planet do not all feel this is immoral, unethical, unprofessional, practice. Moreover, they had the opinion that they are helping the community, and it is their right. It was assessed that 84% of medicine-industry promotional activities are focused on the road to make medical doctors happy. As a medical doctor and other health professionals are principal influencing bodies to choose medicine to be prescribed. Thereafter, medical doctors play the significant role in opening the floodgate to promotes drug sales, whether it is of need or no need. 

Pharmaceutical manufacturing companies are the most powerful industrial and financial transnational group around the planet. The worldwide

Correspondence to: Mainul Haque, Professor of the Unit of Pharmacology, Faculty of Medicine and Defense Health, Universiti Pertahanan Nasional Malaysia (National Defense University of Malaysia), Kem Sungai Besi, 57000 Kuala Lumpur, Malaysia. Land Line: +60 3 9051 3400 Ext 2257 (Office). +60 3 6179 5871 (Home). Cell Phone: + 60 10 926 5543. Email: runuron@gmail.com Orcid No.: 0000-0002-6124-7993
Pharmaceutical Industry Aggressive Medicine Promotional Activity

proceeds for pharma-company were over 1.2 trillion U.S. dollars in 2018, and it goes up to $100 billion from 2017. 49, 50 Additionally, it has been projected that pharmaceutical product spending will reach 1.5 trillion U.S. dollars by 2023. 50 The supervisory body for common people and consumers of the USA named Public Citizen group to consider Big Pharma, as the major fraudster of the US Federal Government law (False Claims Act). 51 On multiple occasions, the drug industry has been identified for many types of unethical work that include swindle, financial corruption, complaints and charges, and disgraces. 52 Nevertheless, the pharmaceutical industry continues to exit and making an improbable and impossible profit with all these illegal, unlawful activities and court verdicts and punishment. 53, 54 Additionally, only 28% of the US nationals have a good view regarding Big Pharma. 55 The second utmost abhorrent industry considered by US citizens is the giant pharmaceutical industry just behind the tobacco industry. 55 The pharma-industry born promotional pieces of literature in both high-income countries (HICs) and LMICs often act as the principal source of information, especially for newly marketed medicine. 27, 56-58 LMICs often suffer poor resources for healthcare and, in parallel, had contemptible regulatory drug control systems. Thereafter, peoples of LMICs are regularly exposed to aggressive, non-authentic, unethical drug promotional activities and its harmful effect with self-purchasing. 59-68 Thereafter, medicines are prescribed by medical doctors, and pharmacists vend and distributed with the intention of patients’ benefit and healthcare interest are lost. This situation reflects the healthcare system of that community has been failed to abide by the elementary medical ethics, regular and average processes, customs, laws, and guidelines. 68-70 As medical doctors are the most considerable elements in pharmaceutical transactions by choosing the specific brand of medicine for their patients. 71 Subsequently, there is an urgent need to develop scientific, ethical, and professional medicine promotional activity. Drug promotional activity needs to be monitored, and pharmaceutical companies should be accountable to regulatory bodies and peoples of the country. Drug industry should also develop social accountability and responsibility towards consumers and common people. In this regard, the state-controlled regulatory bodies and medical professional societies need to act proactively with cooperation to promote public health and people’s healthcare rights. 5, 27, 68
References:


58. Tyrawski J, DeAndrea DC. Pharmaceutical companies and their drugs on social media: a content analysis of drug information on popular social media sites. J Med Internet Res. 2015;17(6):e130. doi:10.2196/jmir.4357


60. Weigmann K. The ethics of global clinical trials: In developing countries, participation in clinical trials is sometimes the only way to access medical treatment. What should be done to avoid exploitation of disadvantaged populations? EMBO Rep. 2015;16(5):566–570. doi:10.15252/embr.201540398


